Cargando…

A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer

The doxorubicin (DOX) prodrug N -[4-doxorubicin- N -carbonyl (oxymethyl) phenyl] O -β-glucuronyl carbamate (DOX-GA3) was synthesised for specific activation by human β-glucuronidase, which is released in necrotic areas of tumour lesions. This novel prodrug was completely activated to the parent drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Houba, P H J, Boven, E, Meulen-Muileman, I H van der, Leenders, R G G, Scheeren, J W, Pinedo, H M, Haisma, H J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363760/ https://www.ncbi.nlm.nih.gov/pubmed/11207053 http://dx.doi.org/10.1054/bjoc.2000.1640

Ejemplares similares

The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.
por: Houba, P. H., et al.
Publicado: (1998)

A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug
por: de Graaf, M, et al.
Publicado: (2002)

A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
por: Haisma, H. J., et al.
Publicado: (1992)

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug
por: Cheng, T L, et al.
Publicado: (1999)

The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.
por: Boven, E., et al.
Publicado: (1992)

A Doxorubicin-Glucuronide Prodrug Released from Nanogels Activated by High-Intensity Focused Ultrasound Liberated β-Glucuronidase
por: Besse, Helena C., et al.
Publicado: (2020)

Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts.
por: Kievit, E., et al.
Publicado: (1996)

Anti-tumour activity and toxicity of the new prodrug9-aminocamptothecin glucuronide (9ACG) in mice
por: Prijovich, Z M, et al.
Publicado: (2002)

Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
por: Platel, D, et al.
Publicado: (1999)

TPGS2000-DOX Prodrug Micelles for Improving Breast Cancer Therapy
por: Tang, Lan, et al.
Publicado: (2021)

Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation
por: Zhang, Yuchen, et al.
Publicado: (2015)

Efficacy of PolyMPC–DOX Prodrugs in 4T1 Tumor-Bearing Mice
por: McRae Page, Samantha, et al.
Publicado: (2014)

Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts
por: Kolfschoten, G M, et al.
Publicado: (2000)

Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound
por: Spiers, Laura, et al.
Publicado: (2023)

Increased doxorubicin uptake and toxicity in multicellular tumour spheroids treated with DC electrical fields
por: Sauer, H, et al.
Publicado: (1999)

Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.
por: Goebel, F. D., et al.
Publicado: (1996)

Secreted and tumour targeted human carboxylesterase for activation of irinotecan
por: Oosterhoff, D, et al.
Publicado: (2002)

CTL–doxorubicin (DOX)–gold complex nanoparticles (DOX–AuGCs): from synthesis to enhancement of therapeutic effect on liver cancer model
por: Liu, Qiqian, et al.
Publicado: (2020)

Correction: CTL–doxorubicin (DOX)–gold complex nanoparticles (DOX–AuGCs): from synthesis to enhancement of therapeutic effect on liver cancer model
por: Liu, Qiqian, et al.
Publicado: (2022)

PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index
por: Casazza, Andrea, et al.
Publicado: (2022)

Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma
por: Van Renterghem, Britt, et al.
Publicado: (2022)

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study
por: Fokkema, E, et al.
Publicado: (2000)

Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model
por: Igarashi, Kentaro, et al.
Publicado: (2018)

Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
por: Schuurhuis, G. J., et al.
Publicado: (1993)

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
por: Monks, N R, et al.
Publicado: (2000)

High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours
por: Koukourakis, M I, et al.
Publicado: (2000)

Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2001)

TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
por: van der Veen, A H, et al.
Publicado: (2000)

The construction of the novel magnetic prodrug Fe(3)O(4)@DOX and its antagonistic effects on hepatocarcinoma with low toxicity
por: Li, Jun, et al.
Publicado: (2020)

Sertoli Cells Loaded with Doxorubicin in Lipid Micelles Reduced Tumor Burden and Dox-Induced Toxicity
por: Das, Mahasweta, et al.
Publicado: (2017)

Mollification of Doxorubicin (DOX)-Mediated Cardiotoxicity Using Conjugated Chitosan Nanoparticles with Supplementation of Propionic Acid
por: Siva, Durairaj, et al.
Publicado: (2022)

A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy
por: Ibsen, Stuart, et al.
Publicado: (2010)

Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives
por: Roemhild, Karolin, et al.
Publicado: (2022)

Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation.
por: Bosslet, K., et al.
Publicado: (1992)

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
por: Boven, E., et al.
Publicado: (1993)

Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: Similarity with glucuronidation in human liver microsomes
por: Kutsuno, Yuki, et al.
Publicado: (2013)

Concentration of testosterone glucuronide in urine from women with breast tumours.
por: Jones, M. K., et al.
Publicado: (1977)

Concentration of Testosterone Glucuronide in Urine from Women with Breast Tumours
por: Grattarola, Renzo
Publicado: (1977)

Concentration of Testosterone Glucuronide in Urine from Women with Breast Tumours
por: Jones, M. K.
Publicado: (1977)

Doxorubicin (DOX) Gadolinium–Gold-Complex: A New Way to Tune Hybrid Nanorods as Theranostic Agent
por: Khan, Memona, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mf6m1qnaopcf093i03pao02k4o